Literature DB >> 30925348

Cannabis as a cause of death: A review.

Olaf H Drummer1, Dimitri Gerostamoulos2, Noel W Woodford2.   

Abstract

Synthetic cannabinoids have caused a large number of emergency presentations to hospitals for adverse cardiovascular events including numerous deaths, particularly for the more potent analogs acting on the CB1 receptor. While smoked cannabis use is often associated with significant changes in heart rate and cardiac output, amongst other physiological changes, it has been rarely considered in the forensic literature as a significant contributory or causal factor in sudden unexpected death. A review of case reports of admissions to hospitals for cardiovascular events was undertaken together with a review of epidemiological studies, and case reports of sudden death attributed, at least in part, to use of this drug. These publications show that use of cannabis is not without its risks of occasional serious medical emergencies and sudden death, with reports of at least 35 persons presenting with significant cardiovascular emergencies who had recently smoked a cannabis preparation. At least 13 deaths from a cardiovascular mechanism have been reported from use of this drug which is very likely to be an under-estimate of the true incidence of its contribution to sudden death. In addition, many cases of stroke and vascular arteritis have also been reported with the latter often involving a limb amputation. While it is a drug with widespread usage among the community with relatively few deaths when faced with a circumstance of very recent use (within a few hours), a positive blood concentration of THC and a possible cardiac-related or cerebrovascular cause of death this drug should be considered, at least, a contributory cause of death in cases of sudden or unexpected death.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arrhythmias; Cardiovascular disease; Forensic; Heart disease; Myocardial infarction; Stroke

Mesh:

Substances:

Year:  2019        PMID: 30925348     DOI: 10.1016/j.forsciint.2019.03.007

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  10 in total

Review 1.  Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Authors:  Eun Yong Chung; Hye Jin Cha; Hyun Kyu Min; Jaesuk Yun
Journal:  Arch Pharm Res       Date:  2021-04-02       Impact factor: 4.946

Review 2.  The Role of Cannabinoids in CNS Development: Focus on Proliferation and Cell Death.

Authors:  Eduardo Cosendey Bockmann; Rafael Brito; Lucianne Fragel Madeira; Luzia da Silva Sampaio; Ricardo Augusto de Melo Reis; Guilherme Rapozeiro França; Karin da Costa Calaza
Journal:  Cell Mol Neurobiol       Date:  2022-08-04       Impact factor: 4.231

3.  Chronic Synthetic Marijuana Use: A Case of First-Onset Seizures as a Withdrawal Symptom.

Authors:  Amber N Edinoff; Prithvi Doppalapudi; Juliana M Fort
Journal:  Health Psychol Res       Date:  2022-04-26

4.  Why do patients come to the emergency department after using cannabis?

Authors:  Shelby K Shelton; Eleanor Mills; Jessica L Saben; Michael Devivo; Kayla Williamson; Diana Abbott; Katelyn E Hall; Andrew A Monte
Journal:  Clin Toxicol (Phila)       Date:  2019-09-16       Impact factor: 4.467

5.  Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.

Authors:  Shivani Sachdev; Samuel D Banister; Marina Santiago; Chris Bladen; Michael Kassiou; Mark Connor
Journal:  Pharmacol Res Perspect       Date:  2020-04

6.  Multiple clinical risks for cannabis users during the COVID-19 pandemic.

Authors:  Ellen Mello Borgonhi; Vanessa Loss Volpatto; Felipe Ornell; Francisco Diego Rabelo-da-Ponte; Felix Henrique Paim Kessler
Journal:  Addict Sci Clin Pract       Date:  2021-01-20

Review 7.  Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

Authors:  Jolanta Weresa; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Barbara Malinowska; Eberhard Schlicker
Journal:  Cells       Date:  2022-03-28       Impact factor: 6.600

8.  The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand.

Authors:  Benedikt Fischer; Dimitri Daldegan-Bueno; Ross Bell; Joseph M Boden; Chris Bullen; Michael Farrell; Wayne Hall; David Newcombe
Journal:  Public Health Pract (Oxf)       Date:  2020-10-29

Review 9.  Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health.

Authors:  Justin Matheson; Bernard Le Foll
Journal:  Front Psychiatry       Date:  2020-09-23       Impact factor: 4.157

10.  Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation.

Authors:  Maximilian Gahr; Julia Ziller; Ferdinand Keller; Rainer Muche; Ulrich W Preuss; Carlos Schönfeldt-Lecuona
Journal:  Eur J Public Health       Date:  2022-04-01       Impact factor: 3.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.